BAYER AG ORD share/ DE000BAY0017 /
2025-05-05 2:30:06 PM | Chg. +478.00 | Volume | Bid5:05:26 PM | Ask5:05:26 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
9,808.00HUF | +5.12% | 180 Turnover: 1.75 mill. |
-Bid Size: - | -Ask Size: - | 9605.64 bill.HUF | - | - |
GlobeNewswire
04-25
Freight Technologies Integrates with Blue Yonder TMS Through Bayer to Optimize Supply Chain Efficien...
GlobeNewswire
04-16
BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial f...
GlobeNewswire
03-07
AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosin...
GlobeNewswire
02-27
UPDATE - YourUpdateTV Speaks with Alanna Morris-Simon from Bayer to Discuss Key Risk Factors for Hea...
GlobeNewswire
02-24
YourUpdateTV Speaks with Alanna Morris-Simon from Bayer to Discuss Key Risk Factors for Heart Diseas...
GlobeNewswire
02-19
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease inves...
GlobeNewswire
02-13
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Fail...
GlobeNewswire
2024-08-02
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
2024-07-11
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
2024-05-30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
2024-05-30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
2024-05-28
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement